ReviewDeutsches Arzteblatt international2023
The Diagnosis and Treatment of Ampullary Carcinoma.
Review in Deutsches Arzteblatt international, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06648746 (Predictors of Therapeutic Success and Adverse Events in Endoscopic Ampullectomy), which is not on this map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Predictors of Therapeutic Success and Adverse Events in Endoscopic Ampullectomy
Who cites it
16 citing papers in PubMed, 5 citations in OpenAlex.
- Routine duodenal papillary biopsy enhances detection of duodenal papillary adenoma in familial adenomatous polyposis patients: a prospective cohort study.British journal of cancer · 2026Observational
- Immunohistochemical profiling of ampullary carcinoma: Molecular subtypes, prognostic markers, and the role of Claudin-18.Virchows Archiv : an international journal of pathology · 2026Article
- Article
- Rare, Yet Targetable: New Perspectives on Ampullary Carcinomas.International journal of molecular sciences · 2026Review
- Pancreaticoduodenectomy with Preservation of a Prior Hepaticojejunostomy for Ampullary Carcinoma: A Case Report.Surgical case reports · 2026Article
- A sequential strategy of upfront radiofrequency ablation followed by endoscopic papillectomy for complex ampullary tumors.Frontiers in medicine · 2026Article
- Muscle index, weight loss, and tumor type predict adjuvant therapy failure in periampullary cancer.Frontiers in nutrition · 2026Article
- Pylorus-Preserving Pancreatoduodenectomy for Ampullary Carcinoma after Esophagectomy with Retrosternal Ileocolonic Interposition: A Case Report.Surgical case reports · 2026Article
- Case Report: Successful staged multidisciplinary management of concurrent duodenal papilla adenocarcinoma and cholelithiasis: a rare case in primary hospital.Frontiers in surgery · 2026Article
- Clinicopathological features and treatment paradigms exploration in advanced ampullary cancer.Frontiers in oncology · 2026Article
- Descriptive Genomic Analysis of Ampullary Carcinoma Utilizing the AACR Project GENIE Dataset.Current issues in molecular biology · 2025Article
- Nomogram for overall survival in ampullary adenocarcinoma using the surveillance, epidemiology, and end results database and external validation.World journal of clinical oncology · 2025Article
- Article
- High plasma histidine concentration predicts a favorable prognosis in patients with ampullary cancer.American journal of cancer research · 2025Article
- Thioredoxin System Protein Expression in Carcinomas of the Pancreas, Distal Bile Duct, and Ampulla in the United Kingdom.Diseases (Basel, Switzerland) · 2024Article
- AGR2: The Covert Driver and New Dawn of Hepatobiliary and Pancreatic Cancer Treatment.Biomolecules · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAmpullary or papillary carcinoma is a malignant tumor arising from the mucosa in the region of the major duodenal papilla, also known as the ampulla of Vater. Uniform treatment recommendations are lacking both for the adjuvant situation and for palliative care.
methodsA selective literature search was carried out in PubMed in order to identify the most informative publications concerning the epidemiology, clinico-pathological background, and surgical and medical treatment of this condition.
resultsAmpullary carcinoma has an incidence of 0.5 to 0.9 per 100 000 persons and a poor prognosis, with a 5-year survival rate of 41% to 45% for locally confined and 4% to 7% for metastatic disease. Most such tumors are of an intestinal or a pan - creaticobiliary immunohistochemical subtype; the latter has a worse prognosis (median survival, 72-80 vs. 33-41 months). Targeted treatment is not yet available for either subtype, nor is there enough scientific evidence available for the formulation of specific therapeutic recommendations in either the adjuvant or the palliative situation. The treatment of choice for ampullary carcinoma is radical oncological resection of the head of the pancreas with systematic lymphadenectomy. Five-year overall survival is between 10% and 75% depending on the stage. No definitive recommendation for adjuvant therapy can be given. Palliative therapy can be oriented to the published treatment strategies for cancer of the colon, pancreas, and bile duct.
conclusionThe current state of the evidence on the treatment of ampullary carcinoma is poor. Therapeutic decisions should be discussed in an interdisciplinary tumor board and should, in our opinion, take the histological subtype into account.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.